Literature DB >> 9555871

Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits: in vivo evidence that lipoprotein(a) may contribute to foam cell formation.

L B Nielsen1, K Juul, B G Nordestgaard.   

Abstract

To investigate a potential role of lipoprotein(a) [Lp(a)] in foam cell formation, we have measured the degradation rates of Lp(a) and LDL in the rabbit aorta in vivo. Lp(a) (or LDL) was labeled with both 113I-TC and 125I and injected into 17 rabbits with extensive aortic atherosclerosis and into 16 rabbits without atherosclerosis. As the protein moiety of the doubly labeled lipoproteins is degraded, 131I-TC is trapped in the cell, whereas 125I diffuses out of the cell. Twenty-four hours after injection, 12 samples of the aorta and biopsies from 9 other tissues were removed. The degradation rate of Lp(a) (percent of plasma pool per gram tissue per day) was less than that of LDL in the adrenals and in the intestine. In contrast, degradation rates of Lp(a) and LDL were similar in liver, spleen, kidney, heart, lung, skeletal muscle, and adipose tissue. In nonlesioned aortic intima-inner media, the degradation rate of Lp(a) was 39% of that of LDL (t test: P <.05 in aortic arch and thoracic aorta), whereas the degradation rates of Lp(a) and LDL were similar in atherosclerotic aortic intima-inner media. Lp(a) degradation rates were markedly increased in atherosclerotic compared with nonlesioned aortic intima-inner media: 28.2+/-9.2 x 10(-7)% and 5.0+/-0.6 x 10(-7)% of the plasma pool per gram tissue per day in the intima-inner media of the proximal segment of atherosclerotic and nonlesioned aorta, respectively (t test: P <.01). These results suggest that the metabolism of Lp(a) is different from that of LDL in nonlesioned arterial intima, possibly reflecting that Lp(a) is degraded by LDL receptors in arterial intima less efficiently than LDL. The results also indicate that the degradation rate of Lp(a) is markedly increased in atherosclerotic lesions of rabbits, supporting the idea that Lp(a) contributes to foam cell formation during the development of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9555871     DOI: 10.1161/01.atv.18.4.641

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  15 in total

Review 1.  Novel metabolic biomarkers of cardiovascular disease.

Authors:  Majken K Jensen; Monica L Bertoia; Leah E Cahill; Isha Agarwal; Eric B Rimm; Kenneth J Mukamal
Journal:  Nat Rev Endocrinol       Date:  2014-09-02       Impact factor: 43.330

Review 2.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

3.  Reduction of cardiovascular risk in subjects with high lipoprotein (a) levels.

Authors:  Giulia Malaguarnera; Saverio Latteri; Vito Emanuele Catania; Michele Malaguarnera
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

Review 4.  New and emerging biomarkers in cardiovascular disease.

Authors:  Leah E Cahill; Monica L Bertoia; Sarah A Aroner; Kenneth J Mukamal; Majken K Jensen
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

5.  Lipoprotein(a) accelerates atherosclerosis in uremic mice.

Authors:  Tanja X Pedersen; Sally P McCormick; Sotirios Tsimikas; Susanne Bro; Lars B Nielsen
Journal:  J Lipid Res       Date:  2010-06-28       Impact factor: 5.922

Review 6.  Adverse effects of conjugated linoleic acids supplementation on circulating lipoprotein (a) levels in overweight and obese individuals: results of a systematic review and meta-analysis of randomized controlled trials.

Authors:  Kimia Leilami; Atefeh Kohansal; Mohsen Mohammadi Sartang; Siavash Babajafari; Zahra Sohrabi
Journal:  Am J Cardiovasc Dis       Date:  2021-02-15

Review 7.  The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk.

Authors:  Sandeep S Mangalmurti; Michael H Davidson
Journal:  Curr Atheroscler Rep       Date:  2011-10       Impact factor: 5.113

Review 8.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

Authors:  Sebhat Erqou; Stephen Kaptoge; Philip L Perry; Emanuele Di Angelantonio; Alexander Thompson; Ian R White; Santica M Marcovina; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-07-22       Impact factor: 56.272

9.  Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction.

Authors:  Takayuki Mitsuda; Yusuke Uemura; Hideki Ishii; Kenji Takemoto; Tomohiro Uchikawa; Masayoshi Koyasu; Shinji Ishikawa; Ayako Miura; Ryo Imai; Satoshi Iwamiya; Yuta Ozaki; Tomohiro Kato; Rei Shibata; Masato Watarai; Toyoaki Murohara
Journal:  Heart Vessels       Date:  2016-03-02       Impact factor: 2.037

10.  FGF21 inhibits apolipoprotein(a) expression in HepG2 cells via the FGFR1-ERK1/2-Elk-1 pathway.

Authors:  Xiaolong Lin; Guohua Li; Xinglan He; Xiaofeng Ma; Kai Zhang; Hai Zhang; Gaofeng Zeng; Zuo Wang
Journal:  Mol Cell Biochem       Date:  2014-04-04       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.